ArticleScientific reports2016
An anti-TNF-α antibody mimetic to treat ocular inflammation.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 27 citations in OpenAlex.
- Corneal strain influences keratocyte proliferation and migration through upregulation of ALDH3A1 expression.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Accelerating corneal wound healing using exosome-mediated targeting of NF-κB c-Rel.Inflammation and regeneration · 2023Article
- Ocular Delivery of Therapeutic Proteins: A Review.Pharmaceutics · 2023Review
- Soluble Papain to Digest Monoclonal Antibodies; Time and Cost-Effective Method to Obtain Fab Fragment.Bioengineering (Basel, Switzerland) · 2022Article
- A Review of Ocular Drug Delivery Platforms and Drugs for Infectious and Noninfectious Uveitis: The Past, Present, and Future.Pharmaceutics · 2021Review
- The effects of intravitreal adalimumab injection on pseudophakic macular edema.BMC research notes · 2020Article
- Site-selective protein conjugation at histidine.Chemical science · 2019Article
- Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.Advanced drug delivery reviews · 2018Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Infliximab is an antibody that neutralizes TNF-α and is used principally by systemic administration to treat many inflammatory disorders. We prepared the antibody mimetic Fab-PEG-Fab (FpF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.